Literature DB >> 25310835

T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement.

Andy C Hsi1, Diane H Robirds, Jingqin Luo, Friederike H Kreisel, John L Frater, TuDung T Nguyen.   

Abstract

T-cell prolymphocytic leukemia (T-PLL) is a rare aggressive mature T-cell leukemia with frequent cutaneous presentation, which has not been well characterized. Among the 25 T-PLLs diagnosed between 1990 and 2013 at our institution, 32% (8/25) showed cutaneous manifestations, presenting as rash, purpura, papules, and ulcers. The skin biopsies showed leukemia cutis with perivascular and periadnexal irregular, small to medium-sized lymphoid infiltrates without epidermotropism. The lymphoid infiltrates were composed of mature CD4+ T cells expressing other T-cell antigens, and a subset (48%) showed dual CD4+/CD8+ coexpression. Higher median absolute peripheral blood lymphocyte count (43.0 vs. 13.0 k/mm; P=0.031) and elevated lactate dehydrogenase levels (P=0.00018) at the time of diagnosis were significantly associated with T-PLLs with skin involvement compared with those without. The extent of bone marrow involvement (P=0.849) and overall survival (P=0.144) was similar in the 2 groups. Fluorescence in situ hybridization or karyotype revealed frequent gains of MYC (67%; n=9), loss of ATM (64%; n=11), and TCL1A rearrangement or inversion 14q (75%; n=12). Gains of TCL1A was also seen (78%; n=9), including in some cases that had concurrent TCL1A rearrangement, whereas TP53 loss was less common (30%; n=10). No correlation was seen between the immunophenotype and morphology versus the presence or absence of skin involvement. These data suggest that cutaneous involvement by T-PLL is relatively common and often associated with significant peripheral blood involvement. The frequent MYC, ATM, and TCL1A alterations identified support that these genes are integral to the pathogenesis of T-PLL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25310835     DOI: 10.1097/PAS.0000000000000272

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  T-cell prolymphocytic leukemia presenting with erythematous patches, plaques, and erythema gyratum-like lesions masquerading as Sézary syndrome.

Authors:  Leah Cohen; Adel Haque; Sophia Ma; Ling Zhang; Lubomir Sokol; Lucia Seminario-Vidal
Journal:  JAAD Case Rep       Date:  2019-08-05

2.  The miR-200c/141-ZEB2-TGFβ axis is aberrant in human T-cell prolymphocytic leukemia.

Authors:  Stefan J Erkeland; Christiaan J Stavast; Joyce Schilperoord-Vermeulen; Giada Dal Collo; Harmen J G Van de Werken; Leticia G Leon; Antoinette Van Hoven-Beijen; Iris Van Zuijen; Yvonne M Mueller; Eric M Bindels; Dick De Ridder; Mies C Kappers-Klunne; Kirsten Van Lom; Vincent H J Van der Velden; Anton W Langerak
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 11.047

Review 3.  Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia.

Authors:  Indumathy Varadarajan; Karen Ballen
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

4.  Brentuximab Vedotin Therapy for Cutaneous Lesions in T-Prolymphocytic Leukemia: A Case Report.

Authors:  Jordan Senchak; Peter Pickens
Journal:  Hematol Rep       Date:  2016-09-28

5.  ZNF506-dependent positive feedback loop regulates H2AX signaling after DNA damage.

Authors:  Somaira Nowsheen; Khaled Aziz; Kuntian Luo; Min Deng; Bo Qin; Jian Yuan; Karthik B Jeganathan; Jia Yu; Henan Zhang; Wei Ding; Jan M van Deursen; Zhenkun Lou
Journal:  Nat Commun       Date:  2018-07-16       Impact factor: 14.919

Review 6.  Genetic Landscape of Peripheral T-Cell Lymphoma.

Authors:  Vivian Hathuc; Friederike Kreisel
Journal:  Life (Basel)       Date:  2022-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.